Back to Search Start Over

Anti-Helicobacter pylori therapy followed by celecoxib on progression of gastric precancerous lesions.

Authors :
Zhang LJ
Wang SY
Huo XH
Zhu ZL
Chu JK
Ma JC
Cui DS
Gu P
Zhao ZR
Wang MW
Yu J
Source :
World journal of gastroenterology [World J Gastroenterol] 2009 Jun 14; Vol. 15 (22), pp. 2731-8.
Publication Year :
2009

Abstract

Aim: To evaluate whether celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, could reduce the severity of gastric precancerous lesions following Helicobacter pylori (H pylori) eradication.<br />Methods: H pylori-eradicated patients with gastric precancerous lesions randomly received either celecoxib (n = 30) or placebo (n = 30) for up to 3 mo. COX-2 expression and activity was determined by immunostaining and prostaglandin E(2) (PGE(2)) assay, cell proliferation by Ki-67 immunostaining, apoptosis by TUNEL staining and angiogenesis by microvascular density (MVD) assay using CD31 staining.<br />Results: COX-2 protein expression was significantly increased in gastric precancerous lesions (atrophy, intestinal metaplasia and dysplasia, respectively) compared with chronic gastritis, and was concomitant with an increase in cell proliferation and angiogenesis. A significant improvement in precancerous lesions was observed in patients who received celecoxib compared with those who received placebo (P < 0.001). Of these three changes, 84.6% of sites with dysplasia regressed in patients treated with celecoxib (P = 0.002) compared with 60% in the placebo group, suggesting that celecoxib was effective on the regression of dysplasia. COX-2 protein expression (P < 0.001) and COX-2 activity (P < 0.001) in the gastric tissues were consistently lower in celecoxib-treated patients compared with the placebo-treated subjects. Moreover, it was also shown that celecoxib suppressed cell proliferation (P < 0.01), induced cell apoptosis (P < 0.01) and inhibited angiogenesis with decreased MVD (P < 0.001). However, all of these effects were not seen in placebo-treated subjects. Furthermore, COX-2 inhibition resulted in the up-regulation of PPARgamma expression, a protective molecule with anti-neoplastic effects.<br />Conclusion: H pylori eradication therapy followed by celecoxib treatment improves gastric precancerous lesions by inhibiting COX-2 activity, inducing apoptosis, and suppressing cell proliferation and angiogenesis.

Details

Language :
English
ISSN :
2219-2840
Volume :
15
Issue :
22
Database :
MEDLINE
Journal :
World journal of gastroenterology
Publication Type :
Academic Journal
Accession number :
19522023
Full Text :
https://doi.org/10.3748/wjg.15.2731